News FDA declines to approve needle-free epinephrine from ARS Shares in ARS Pharmaceuticals were in freefall in pre-market trading this morning as it emerged that the FDA had declined to approve its application for its lead product,
Views & Analysis What doctors say about EpiPen pricing The furore over Mylan’s ‘price gouging’ in relation to EpiPen in the US went global, thanks to social media.
News Mylan responds to price backlash with generic EpiPen Company launches cut-price generic alongside existing branded version
R&D Modelling biologics: Challenges and opportunities, with Dr D... From AAPS 2025, an interview with Dr Dhaval Shah, professor of pharmaceutical sciences at the University of Buffalo and former Pfizer researcher.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.